I appreciate Ms. Bennett's generous offer not to do the nanotechnology session, but that was the only one that we had suggested.
If you look at the five remaining sessions, four of them you suggested, and there's only one that we suggested. In the notion of fairness, I think it would be good to displace another one of the studies. Given the comments we heard from Mr. Butler-Jones, maybe we don't need to do the draft report on the HIV vaccine manufacturing facility. I'm not sure how long that's going to take, but I don't think we should cancel the session on the potential risks and benefits of nanotechnology.